Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $22.0 million.

  • Corcept Therapeutics' Change in Accured Expenses rose 1202.1% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 22852.09%. This contributed to the annual value of $38.2 million for FY2024, which is 11668.08% up from last year.
  • Corcept Therapeutics' Change in Accured Expenses amounted to $22.0 million in Q3 2025, which was up 1202.1% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Change in Accured Expenses registered a high of $22.0 million during Q3 2025, and its lowest value of -$19.0 million during Q4 2023.
  • Its 5-year average for Change in Accured Expenses is $4.3 million, with a median of $3.7 million in 2021.
  • Examining YoY changes over the last 5 years, Corcept Therapeutics' Change in Accured Expenses showed a top increase of 27309.34% in 2023 and a maximum decrease of 171406.78% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Change in Accured Expenses stood at $3.4 million in 2021, then crashed by 64.84% to $1.2 million in 2022, then crashed by 1714.07% to -$19.0 million in 2023, then surged by 156.24% to $10.7 million in 2024, then skyrocketed by 105.24% to $22.0 million in 2025.
  • Its Change in Accured Expenses stands at $22.0 million for Q3 2025, versus $1.1 million for Q2 2025 and -$5.9 million for Q1 2025.